Education And Data Will Bolster Biosimilar-To-Biosimilar Switching
Sandoz Executive Hillel Cohen Discusses Misinformation And How It Can Be Overcome
Executive Summary
In the wake of a recent paper which concluded that moving patients between two different biosimilar versions of the same brand biologic was safe and effective, Generics Bulletin speaks to Sandoz Inc executive director of scientific affairs Hillel Cohen about the growing importance of – and challenges to – biosimilar-to-biosimilar switching.